BBIO Aug 2024 40.000 call
| Previous close | 1.8000 |
| Open | 1.4000 |
| Bid | 0.8500 |
| Ask | 2.2500 |
| Strike | 40.00 |
| Expiry date | 2024-08-16 |
| Day's range | 1.4000 - 1.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 6.45k |
GlobeNewswireBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on June 6, 2024, the compensation committee of BridgeBio’s board of directors approved equity grants to 18 new employees in restricted stock units for an aggregate of 90,591 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restri
- GlobeNewswire
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that Neil Kumar, Ph.D., founder and CEO of BridgeBio, will present at the Goldman Sachs Annual Global Healthcare Conference in Miami, FL on Wednesday, June 12 at 3:20 pm EDT. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” pa
Investor's Business DailyBridgeBio Stock Gives Up Gains On Comparisons To BioMarin Drug
BridgeBio stock gave up gains midday Tuesday after releasing a Phase 2 study on a growth disorder treatment.
